Pharmafile Logo
Pharmafocus logo
Advanced Search

Alzheimer’s

Showing 15 posts of 148 posts found.

mice

Flickering LEDs could light the way for new Alzheimer’s treatment

December 8, 2016
Medical Communications, Research and Development Alzheimer's, Cognito therapeutics, mice

Research to find a potential new treatment for Alzheimer’s was hit a blow late last month, as Eli Lilly discontinued …

News
shutterstock_212432119

New Alzheimer’s research edges closer to treatment & prevention

December 7, 2016
Research and Development Alzheimer's

A new study has shed light on the possible prevention and treatment of Alzheimer’s disease thanks to findings centred on …

News
161201120435_1_900x600

New molecular-binding technique promises accelerated drug development

December 5, 2016
Research and Development, Sales and Marketing Alzheimer's, Cancer, Indiana University-Purdue University Indianapolis

Researchers at the School of Science at Indiana University-Purdue University Indianapolis (IUPUI) have claimed to have designed a new molecular …

News
lilly2_web

Lilly forced to abandon Alzheimer’s drug after failed trial

November 24, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Alzheimer's disease, Eli Lilly

Eli Lilly announced that the results of its ‘Expedition 3’ trial for an experimental Alzheimer’s disease drug meant that they would …

News
merck_and_co

MSD’s Alzheimer’s study could break new ground for treatment

November 3, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, MSD, clinical trials

MSD, known as Merck in North America, has published results of a Phase I trial of verubecestat. The drug is …

News
alzheimers_brain

Alzheimer’s drug failure sends Lundbeck’s shares crashing

September 23, 2016
Medical Communications, Research and Development Alzheimer's, Lundbeck, cultural failings

Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of …

News

FDA fast track designation for Biogen’s investigational Alzheimer’s treatment

September 2, 2016
Medical Communications, Research and Development Alzheimer's, Alzheimer’s, Biogen, FDA, aducanumab, fast track

Biogen has announced that its investigational Alzheimer’s disease treatment aducanumab has been granted fast track designation by the FDA. The …

News
shutterstock_212432119

LMTX fails Phase III trial, monotherapy benefits seen

July 28, 2016
Research and Development Alzheimer's, LMTX, TauRX, phase III, phase III failure

TauRX Therapeutics has reported Phase III clinical trial results for its novel tau aggregation inhibitor LMTX. The results indicated that …

News
biogen_austria_238

Biogen Alzheimer’s treatment accepted into EMA’s PRIME scheme

June 2, 2016
Research and Development, Sales and Marketing Alzheimer's, Biogen, EMA, PRIME, accelerated approval

Biogen (NASDAQ: BIIB) has announced that the European Medicines Agency (EMA) has accepted its investigational treatment for Alzheimer’s disease, aducanumab, …

News
pharma_pill_manufacturing

AstraZeneca and Eli Lilly to enter Phase III on Alzheimer’s clinical trials

April 8, 2016
Medical Communications AZD3293, Alzheimer's, Alzheimers, AstraZeneca, amaranth, clinical trial, lilly, phase III

AstraZeneca and Eli Lilly have announced the continuation of their clinical trial for people with early Alzheimer’s disease into Phase …

News
handshake

Allergan to partner with Heptares in Alzheimer’s disease collaboration

April 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Alzheimer's, Heptares, R&D, collaboration, commercialisation, h1, h4, neurological disorders, partnership, research and development, treatments

Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan (NYSE:AGN) has announced a new …

News
alzheimers

South Florida Uni begins £875,000 dementia drug research programme

March 1, 2016
Manufacturing and Production, Research and Development Alzheimer's

Funding from a consortium worth £875,000 pounds has helped kick start a new dementia drug research program at the University …

News
heptares_logo

Heptares announces positive early-stage dementia trial results

February 10, 2016
Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia

Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …

News

Alzheimer’s drugs prescriptions rise six-fold in a decade

January 19, 2016
Manufacturing and Production Alzheimer's, Alzheimer's disease, NHSIC, dementia, prescribing

The number of prescriptions dispensed in England for approved medicines to treat Alzheimer’s increased from 502,000 in 2004 to 3 …

News
Alzheimer's brain

The case for adaptive trials in dementia

January 6, 2016
Manufacturing and Production, Research and Development Alzheimer's, Alzheimer's disease, adaptive trials, research

An ageing population and widespread chronic neuro-degenerative disease will make dementia an ever increasing burden on society, families and the …

Feature

Latest content

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024

Merck to acquire Mirus Bio for $600m

May 23, 2024

Rare disease clinical trials: the urgent need for patients to be heard

May 22, 2024